Trevi Therapeutics
TRVI
55 hedge funds and large institutions have $106M invested in Trevi Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
4% more funds holding
Funds holding: 53 → 55 (+2)
5.03% less ownership
Funds ownership: 81.28% → 76.25% (-5%)
9% less capital invested
Capital invested by funds: $117M → $106M (-$10.6M)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$101K |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$93.7K |
| 3 |
State Street
Boston,
Massachusetts
|
+$63.3K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$56.6K |
| 5 |
Jane Street
New York
|
+$55.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$196K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$188K |
| 3 |
IAM
Innovis Asset Management
Chicago,
Illinois
|
-$103K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$75.4K |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$61.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Legal & General Group
London,
United Kingdom
| $8.66K | – | – | – |
|
|
AIP
52
Ameritas Investment Partners
Lincoln,
Nebraska
| $7.5K | – | – | – |
|
|
NS
53
NBC Securities
Birmingham,
Alabama
| $4K | +$4.52K | +2,000 | New |
|
54
Fidelity Investments
Boston,
Massachusetts
| $3.44K | +$1.57K | +694 | +78% |
|
55
Citigroup
New York
| $94 | -$27.9K | -12,355 | -100% |
|
|
IAM
56
Innovis Asset Management
Chicago,
Illinois
| – | -$103K | -43,232 | Closed |
|
57
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$27.7K | -11,571 | Closed |
|
58
LPL Financial
San Diego,
California
| – | -$23.9K | -10,000 | Closed |
|
|
ZIM
59
Zacks Investment Management
Chicago,
Illinois
| – | -$23.9K | -10,000 | Closed |
|
TRVI Hedge Fund Activity: Q3 2023 in Review
55 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2023, worth a combined $106M — down 9% from $117M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TRVI positions and 4 closed out — a net gain of 2 holders — while 13 added to existing stakes and 17 trimmed.
The largest buyer was Vanguard Group, adding an estimated $101K. The largest seller was BlackRock, cutting an estimated $196K.
- 55 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2023, up from 53 in Q2 2023.
- Funds reported $106M of Trevi Therapeutics stock for Q3 2023, down 9% quarter-over-quarter.
- 6 funds opened new Trevi Therapeutics positions in Q3 2023 and 4 closed out, a net change of +2 holders.
- The largest Trevi Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $101K added.
- The largest Trevi Therapeutics seller in Q3 2023 was BlackRock, an estimated $196K sold.
Based on aggregated 13F filings for Q3 2023.